Attempted Passive Prophylaxis with a Monoclonal Anti-Burkholderia Pseudomallei Exopolysaccharide Antibody in a Murine Model of Melioidosis

REFERENCES

• Dance D.A.B. Pseudomonas pseudomallei: danger in the paddy fields. Trans. R. Soc. Trop. Med. Hyg. 1991; 85: 1–3, [CSA]
   PubMed Web of Science ®Google Scholar
• Dance D.A.B., King C., Aucken H., Knott C.D., West P.G., Pitt T.L. An outbreak of melioidosis in imported primates in Britain. Vet. Record. 1992; 130: 525–529, [CSA]
   PubMed Web of Science ®Google Scholar
• Dance D.A.B., Smith M.D., Aucken H., Pitt T.L. Imported melioidosis in England and Wales. Lancet 1999; 353: 208, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mollaret H.H. L’affaire du jardin des plantes ou comment la mélioïdose fit son apparition en France. Med. Mal. Infect. 1988; 18: 643–654, [CSA]
   Google Scholar
• Torrens J.K., McWhinney P.H., Tompkin D.S. A deadly thorn: a case of importated melioidosis. Lancet, 1999; 353: 1016, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dance D.A.B. Melioidosis: the tip of the iceberg. Clin. Microbiol. Rev. 1991; 4: 52–60, [CSA]
   PubMed Web of Science ®Google Scholar
• Woods D.E., DeShazer D., Moore R.A., Brett P.J., Burtnick M.N., Reckseidler S.L., Senkiw M.D. Current studies on the pathogenesis of melioidosis. Microbes Infect 1999; 2: 157–162, [CSA], [CROSSREF]
   Google Scholar
• 8.Centers for Disease Control and Prevention. Division of Bacterial and Mycotic Diseases: disease information, melioidosis. [Online.]
   Google Scholar
• Mays E.E., Ricketts E.A. Melioidosis: recrudescence associated with bronchiogenic carcinoma twenty-six years following initial geographic exposure. Chest 1975; 68: 261–263, [CSA]
   PubMed Web of Science ®Google Scholar
• Chaowagul W., Supputamongkol Y., Dance D.A.B., Rajchanuvong A., Pattara-arechachai J., White N. J. Relapse in melioidosis: incidence and risk factors. J. Infect. Dis. 1993; 168: 1181–1185, [CSA]
   PubMed Web of Science ®Google Scholar
• White N.J., Dance D.A.B., Chaowagul W., Wattanagoon Y., Wuthiekanum V., Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; ii: 697–702, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Harley V. S., Dance D. A. B., Tovey G., McCrossan M. V., Drasar B. S. An ultrasructural study of the phagocytosis of Burkholderia pseudomallei. Microbios 1998; 94: 35–45, [CSA]
   PubMedGoogle Scholar
• Harley V.S., Dance D.A.B., Drasar B.S., Tovey G. Effects of Burkholderia pseudomallei and other species on eukaryotic cells in tissue culture. Microbios 1998; 96: 71–93, [CSA]
   PubMedGoogle Scholar
• Jones A.L., Beveridge T.J., Woods D.E. Intracellular survival of Burkholderia pseudomallei. Infect. Immun. 1996; 64: 782–790, [CSA]
   PubMed Web of Science ®Google Scholar
• Kespichayawattana W., Rattanachetkul S., Wanun T., Utaisincharoen P., Sirishinha S. Burkholderia pseudomallei induces cell fusion and actin-associated membrane protrusion: a possible mechanism for cell-to-cell spreading. Infect. Immun. 2000; 68: 5377–5384, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Santanirand P., Harley V.S., Dance D.A.B., Drasar B.S., Bancroft G.J. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect. Immun. 1999; 67: 3593–3600, [CSA]
   PubMed Web of Science ®Google Scholar
• Ulett G.C., Ketheesan N., Hirst R.H. Macrophage-lymphocyte interactions mediate anti-Burkholderia pseudomallei activity. FEMS Immunol. Med. Mic. 1998; 21: 283–286, [CSA]
   PubMedGoogle Scholar
• Ulett G.C., Ketheesan N., Hirst R.H. Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infect. Immun. 2000; 68: 2034–2042, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cooper A.M., Dalton D.K., Stewart T.A. Disseminated tuberculosis in gamma interferon-disrupted mice. J. Exp. Med. 1993; 178: 2243–2247, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Muotiala A., Mäkelä P.H. The role of IFN-γ in murine Salmonella typhimurium infection. Microb. Pathogenesis. 1990; 8: 135–141, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brett P.J., Woods D.E. Pathogenesis of and immunity to melioidosis. Acta Trop 2000; 74: 201–210, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brett P.J., Mah D.C.W., Woods D.E. Isolation and characterization of Pseudomonas pseudomallei flagellin proteins. Infect. Immun. 1994; 62: 1914–1919, [CSA]
   PubMed Web of Science ®Google Scholar
• Brett P.J., Woods D.E. Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect. Immun. 1996; 64: 2824–2828, [CSA]
   PubMed Web of Science ®Google Scholar
• Bryan L.E., Wong S., Woods D.E., Dance D.A.B., Chaowagul W. Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. Can. J. Infect. Dis. 1994; 5: 170–178, [CSA]
   PubMedGoogle Scholar
• Zeitlin L., Cone R.A., Whaley K.J. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg. Infect. Dis. 1999; 5: 54–64, [CSA]
   PubMed Web of Science ®Google Scholar
• Zeitlin L., Cone R.A., Moench T.R., Whaley K.J. Preventing infectious disease with passive immunization. Microbes Infect 2000; 2: 701–708, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Steinmetz I., Nimtz M., Wray V., Häussler S., Reganzerowski A., Brenneke B. Exopolysaccharides of Burkholderia pseudomallei. Acta Trop 2000; 74: 211–214, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Otterbein C.-K., Splettstößer W.D., Linde H.-J., Grunow R., Wolf H., Finke E.-J., Neubauer H. Production and Characterization of a Monoclonal Antibody reactive with a 64kDa Somatic Antigen of Burkholderia cepacia. Hybridoma 1998; 17: 143–150, [CSA]
   PubMedGoogle Scholar
• Gauthier Y.P., Thibault F.M., Paucod J.C., Vidal D.R. Protease production by Burkholderia pseudomallei and virulence in mice. Acta Trop 2000; 74: 215–220, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gauthier Y.P., Hagen R.M., Brochier G., Neubauer H., Splettstoesser W.D., Finke E-J., Vidal D.R. Study on the pathophysiology of experimental Burkholderia pseudomallei infection in mice. FEMS Immunol. Med. Mic. 2001; 30: 53–63, [CSA]
   PubMed Web of Science ®Google Scholar
• Hoppe I., Brenneke B., Rohde M., Kreft A., Häubler S., Reganzerowski A., Steinmetz I. Characterization of a murine model of melioidosis: comparison of different strains of mice. Infect. Immun. 1999; 67: 2891–2900, [CSA]
   PubMed Web of Science ®Google Scholar
• Inglis T.J., Golledge C.L., Clair A., Harvey J. Case report: recovery from persistent septicemic melioidosis. Am. J. Trop. med. Hyg. 2001; 65: 76–82, [CSA]
   PubMed Web of Science ®Google Scholar
• Suputtamongkol Y., Rajchanuvong A., Chaowagul W., Dance D.A.B., Smith M.D., Wuthiekanum V., Walsh A.L., Pukrittayakamee S., White N. J. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin. Infect. Dis. 1994; 19: 846–853, [CSA]
   PubMed Web of Science ®Google Scholar
• Russel P., Eley S.M., Ellis J., Green M., Bell D.L., Kenny D.J., Titball R.W. Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J. Antimicrob. Chemoth. 2000; 45: 813–818, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 2002; 8: 833–843, [CSA]
   PubMed Web of Science ®Google Scholar
• Dunn D.L., Ewald D.C., Chandan N., Cerra F.B. Immunotherapy of Gram-negative bacterial sepsis. A single murine monoclonal antibody provides cross-genera protection. Arch. Surg. 1986; 121: 58–62, [CSA]
   PubMedGoogle Scholar
• Gaglani M.J., Baker C.J., Edwards M.S. Contribution of antibody to neutrophil-mediated killing of Enterococcus faecalis. J. Clin. Immunol. 1997; 17: 478–484, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Perry M.P., MacLean L.L., Schollaardt T., Bryan L.E., Ho M. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect. Immun. 1995; 63: 3348–3352, [CSA]
   PubMed Web of Science ®Google Scholar
• Steinmetz I., Rhode M., Brenneke B. Purification and characterization of an exopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. Infect. Immun. 1995; 63: 3959–3965, [CSA]
   PubMed Web of Science ®Google Scholar
• Ho M., Schollaardt T., Smith M.D., Perry M.B., Brett P.J., Chaowagul W., Bryan L. E. Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect. Immun. 1997; 65: 3648–3653, [CSA]
   PubMed Web of Science ®Google Scholar
• Huebner J., Quaas A., Krueger W.A., Goldman D.A., Pier G.B. Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and -resistant enterococci. Infect. Immun. 2000; 68: 4631–4636, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Collins M.S., Ladehoff D., Mehton N.S. Therapy of established experimental Pseudomonas aeruginosa infections with oral ciprofloxacin and five human monoclonal antibodies against lipopolysaccharide antigens. Pseudomonas aeruginosa in Human Diseases, J. Y. Homma, H. Tanimoto, I.A. Holder, N. Hoiby, G. Döring. Karger, Basel 1991; 44: 185–195
   Google Scholar
• Leakey A.L., Ulett G.C., Hirst R.G. BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb. Pathogenesis. 1998; 24: 269–275, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Veljanov D., Vesselinova A., Nikolova S., Najdenski H., Kussovski V., Markova N. Experimental melioidosis in inbred mouse strains. Zbl. Bakt. 1996; 283: 351–359, [CSA]
   PubMedGoogle Scholar
• Liu B., Koo G.C., Yap E.H., Chua K.L., Gan Y- H. Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect. Immun. 2002; 70: 504–511, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dumont F.J. Modulation of Th1 and Th2 responses for immunotherapy. Expert Opin. Ther. Patents. 2002; 12: 1–27, [CSA]
   Web of Science ®Google Scholar
• Raupach B., Kaufmann S.H.E. Immune responses to intracellular bacteria. Curr. Opin. Immunol. 2001; 13: 417–428, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., Presky D.H. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic mmune responses. Annu. Rev. Immunol. 1998; 16: 495–521, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cooper A.M., Dalton D.K., Stewart T.A. Disseminated tuberculosis in gamma interferon-disrupted mice. J. Exp. Med. 1993; 178: 2243–2247, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Barnes J.L., Ulett G.C., Ketheesan N., Summers P.M., Hirst R.G. Induction of multiple chemokine and colony-stimulating factor genes in experimental Burkholderia pseudomallei infection. Immunol. Cell Biol. 2001; 79: 490–501, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Miyagi K., Kawakami K., Saito A. Role of reactive nitrogen and oxygen intermediates in gamma interferon-stimulated murine macrophage bactericidal activity against Burkholderia pseudomallei. Infect. Immun. 1997; 65: 4108–4113, [CSA]
   PubMed Web of Science ®Google Scholar
• Utaisincharoen P., Tangthawomchaikul N., Kespichayawattana W., Chaisuriya P., Sirisinha S. Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: a possible mechanism of evading macrophage killing. Microbiol. Immunol. 2001; 45: 307–313, [CSA]
   PubMed Web of Science ®Google Scholar
• Car B.D., Eng V.M., Schnyder B., Ozmen L., Huang S., Gallay P., Heumann D., Aguet M., Ryffel B. Interferon gamma receptor deficient mice are resistant to endotoxic shock. J. Exp. Med. 1994; 179: 1437–1444, [CSA]
   PubMed Web of Science ®Google Scholar
• Heremans H., VanDamme J., Dillen C., Dijkmans R., Billiau A. Interferon gamma, a mediator of lethal polysaccharide-induced Schwartzman-like shock reactions in mice. J. Exp. Med. 1990; 171: 1853–1869, [CSA]
   PubMed Web of Science ®Google Scholar
• Friedland J.S., Supputamongkol Y.D., Remick G., Chaowagul W., Strieter R.M, Kunkel S.L, White N.J., Griffin G.E. Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect. Immun. 1992; 60: 2402–2408, [CSA]
   PubMed Web of Science ®Google Scholar
• Lauw F.N., Simpson A.J.H., Prins JM., Van Devente S.J.H., Chaowagul W., White N.J., Van der Poll T. The CXC Chemokines gamma interferon (IFN-γ)-inducible protein 10 and monokine induced by IFN-γ are released during severe melioidosis. Infect. Immun. 2000; 68: 3888–3893, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Simpson A.J.H., Smith M.D., Weverling G.J., Suputtamongkol Y., Angus B.J., Chaowagul W., White N.J., van Deventer S.J.H., Prins J.M. Prognostic value of cytokine concentrations (tumor necrosis factor-α, interleukin-6, and interleukin-10) and clinical parameters. J. Infect. Dis. 2000; 181: 621–625, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Biron C.A., Gazzinelli R.T. Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Curr. Opin. Immunol. 1995; 7: 485–496, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hack C.E., Aarden L.A., Thijs L.G. Role of cytokines in sepsis. Adv. Immunol. 1997; 66: 101–195, [CSA]
   PubMed Web of Science ®Google Scholar